If it takes a mature market to support a specialty consultant class, then the appearance of Genomic Healthcare Strategies, with its focus on pharmacogenomic-based medicine, could be a sign that the field is establishing itself.

Though it hasn’t yet made any money from clients, the new consulting company hopes to cater to individuals, companies, and “policy organizations” in molecular medicine, genomics, and therapeutics, by helping them “understand value and monetize opportunities,” said Kevin Batchelder, a consultant for the Charlestown, Mass.-based company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.